Beijing Tong Ren Tang Chinese Medicine Yönetim

Yönetim kriter kontrolleri 0/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Wang Chi

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	less than a year
CEO sahipliği	n/a
Yönetim ortalama görev süresi	less than a year
Yönetim Kurulu ortalama görev süresi	2.3yrs

Son yönetim güncellemeleri

Recent updates

CEO

Wang Chi (49 yo)

less than a year

Görev süresi

Mr. Wang Chi is Executive Director and Chief Executive Officer of Beijing Tong Ren Tang Chinese Medicine Company Limited from May 10, 2024. Mr. Chi has experience in Medical and Pharmaceutical industry. Mr...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Hai Ou Gu	Executive Chairman of the Board	less than a year	Veri yok	Veri yok
Fei Chen	Executive Director & Executive Deputy GM	less than a year	HK$975.00k	0.0073% HK$ 516.9k
Wang Chi	CEO & Executive Director	less than a year	Veri yok	Veri yok
Fung Yi Tsang	CFO & Company Secretary	4.6yrs	Veri yok	Veri yok
Zheng Guo Shen	Deputy GM & General Counsel	no data	Veri yok	Veri yok

0.8yrs

Ortalama Görev Süresi

50yo

Ortalama Yaş

Deneyimli Yönetim: 3613 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 0.8 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Hai Ou Gu	Executive Chairman of the Board	less than a year	Veri yok	Veri yok
Fei Chen	Executive Director & Executive Deputy GM	4.8yrs	HK$975.00k	0.0073% HK$ 516.9k
Wang Chi	CEO & Executive Director	less than a year	Veri yok	Veri yok
Yok-Sing Tsang	Independent Non-Executive Director	7.3yrs	HK$288.00k	Veri yok
Ngai Chi Chan	Independent Non-Executive Director	11.7yrs	HK$288.00k	Veri yok
Li Feng	Non-Executive Director	2.3yrs	Veri yok	Veri yok
Hong Xi Xu	Independent Non-Executive Director	1.8yrs	HK$240.00k	Veri yok

2.3yrs

Ortalama Görev Süresi

53yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 3613 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 2.3 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2024/12/24 07:24
Gün Sonu Hisse Fiyatı	2024/12/24 00:00
Kazançlar	2024/06/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Beijing Tong Ren Tang Chinese Medicine Company Limited 8 Bu analistlerden 2, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Yanyin Zhu	China International Capital Corporation Limited
null null	CMB International Securities Limited
Christina Chen	HSBC

Beijing Tong Ren Tang Chinese Medicine Yönetim

Yönetim kriter kontrolleri 0/4

Anahtar bilgiler

Son yönetim güncellemeleri

Less than half of directors are independent

Beijing Tong Ren Tang Chinese Medicine Company Limited Appoints Wang Chi as an Executive Director and a Member of the Competition Executive Committee

Beijing Tong Ren Tang Chinese Medicine Company Limited Announces CEO Changes

Beijing Tong Ren Tang Chinese Medicine Company Limited, Annual General Meeting, May 31, 2024

Less than half of directors are independent

Beijing Tong Ren Tang Chinese Medicine Company Limited Appoints Gu Hai Ou as Executive Director, Chairman of Board and Authorised Representative

Recent updates

Now 20% undervalued after recent price drop

Now 20% undervalued after recent price drop

Investor sentiment improves as stock rises 22%

First half 2024 earnings released: EPS: HK$0.26 (vs HK$0.32 in 1H 2023)

Beijing Tong Ren Tang Chinese Medicine Company Limited to Report First Half, 2024 Results on Aug 30, 2024

Beijing Tong Ren Tang Chinese Medicine Company Limited Approves Final Dividend for the Year Ended December 31, 2023

Now 22% overvalued after recent price rise

Upcoming dividend of HK$0.33 per share

Less than half of directors are independent

Beijing Tong Ren Tang Chinese Medicine Company Limited Appoints Wang Chi as an Executive Director and a Member of the Competition Executive Committee

Now 21% overvalued after recent price rise

Full year 2023 earnings released: EPS: HK$0.65 (vs HK$0.77 in FY 2022)

Beijing Tong Ren Tang Chinese Medicine Company Limited Announces CEO Changes

Beijing Tong Ren Tang Chinese Medicine Company Limited, Annual General Meeting, May 31, 2024

Full year 2023 earnings released: EPS: HK$0.65 (vs HK$0.77 in FY 2022)

Beijing Tong Ren Tang Chinese Medicine Company Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on June 17,2024

New minor risk - Financial data availability

Investor sentiment deteriorates as stock falls 17%

Beijing Tong Ren Tang Chinese Medicine Company Limited to Report Fiscal Year 2023 Results on Mar 31, 2024

Now 21% undervalued after recent price drop

Less than half of directors are independent

Beijing Tong Ren Tang Chinese Medicine Company Limited Appoints Gu Hai Ou as Executive Director, Chairman of Board and Authorised Representative

Beijing Tong Ren Tang Chinese Medicine Company Limited to Report Nine Months, 2023 Results on Oct 31, 2023

Beijing Tong Ren Tang Chinese Medicine Company Limited Announces Resignation of Lin Man as Executive Director, Chief Operating Officer, Member of Competition Executive Committee

Beijing Tong Ren Tang Chinese Medicine Company Limited Announces Retirement of Ding Yong Ling as Executive Director and Chairman of the Board

First half 2023 earnings released: EPS: HK$0.32 (vs HK$0.26 in 1H 2022)

Beijing Tong Ren Tang Chinese Medicine Company Limited to Report First Half, 2023 Results on Aug 10, 2023

Beijing Tong Ren Tang Chinese Medicine Company Limited Approves Final Dividend for the Year Ended 31 December 2022

Upcoming dividend of HK$0.33 per share at 2.1% yield

Full year 2022 earnings released: EPS: HK$0.77 (vs HK$0.73 in FY 2021)

Less than half of directors are independent

Beijing Tong Ren Tang Chinese Medicine Company Limited to Report Nine Months, 2022 Results on Oct 31, 2022

Upcoming dividend of HK$0.25 per share

Beijing Tong Ren Tang Chinese Medicine Company Limited Proposes Special Interim Dividend, Payable on 21 October 2022

Less than half of directors are independent

COO & Executive Director recently bought HK$183k worth of stock

First half 2022 earnings released

Beijing Tong Ren Tang Chinese Medicine Company Limited Appoints Feng Li as Executive Director

Beijing Tong Ren Tang Chinese Medicine Company Limited to Report First Half, 2022 Results on Aug 12, 2022

Investor sentiment improved over the past week

Upcoming dividend of HK$0.28 per share

Full year 2021 earnings released: EPS: HK$0.73 (vs HK$0.65 in FY 2020)

Beijing Tong Ren Tang Chinese Medicine Company Limited Proposes Final Dividend for the Year Ended 31 December 2021

Beijing Tong Ren Tang Chinese Medicine Company Limited to Report Fiscal Year 2021 Results on Mar 07, 2022

Investor sentiment improved over the past week

CEO & Executive Director recently bought HK$178k worth of stock

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Beijing Tong Ren Tang Chinese Medicine Company Limited Approves Final Dividend for the Year Ended 31 December 2020

Investor sentiment improved over the past week

Upcoming dividend of HK$0.24 per share

Full year 2020 earnings released: EPS HK$0.65 (vs HK$0.66 in FY 2019)

Beijing Tong Ren Tang Chinese Medicine Company Limited, Annual General Meeting, May 28, 2021

Beijing Tong Ren Tang Chinese Medicine Company Limited Announces Appointment of Chen Fei as Executive Director

CEO & Executive Director Huan Ping Zhang has left the company

Full year 2020 earnings released: EPS HK$0.65 (vs HK$0.66 in FY 2019)

Revenue beats expectations

Beijing Tong Ren Tang Chinese Medicine Company Limited to Report Fiscal Year 2020 Results on Mar 11, 2021

Investor sentiment improved over the past week

New 90-day high: HK$9.58

Beijing Tong Ren Tang Chinese Medicine Company Limited (SEHK:3613) entered into the Sale and Purchase Agreement to acquire 40% stake in Beijing Tong Ren Tang WM Dianorm Biotech Co., Limited from WM Dianorm Biotech Co., Limited for RMB 33.1 million.

New 90-day high: HK$9.25

New 90-day low: HK$8.04

New 90-day low: HK$8.20

Chairman recently bought HK$257k worth of stock

New 90-day low - HK$8.66

First half earnings released

Beijing Tong Ren Tang Chinese Medicine Company Limited to Report First Half, 2020 Results on Aug 13, 2020

New 90-day low - HK$9.28